ADQ announces it will acquire Pharmax Pharmaceuticals, as well as investing in a minority stake in Biocon Biologics.
Alvotech and Kamada announce agreement to commercialise six biosimilar products in Israel. The first product is expected to be launched in Israel in 2022.
Alvotech and STADA announce agreement for the commercialisation of seven biosimilars in all key European markets and selected markets outside Europe. Under the agreement, Alvotech will be responsible for the development, registration and supply of the biosimilars,...
Biocon and Evotec announce strategic licensing agreement for an early-stage biosimilar. Under this agreement, Biocon will take the asset through end-to-end development, IND filing, manufacturing and commercialisation and post-regulatory approval.
Biocon announces purchase of 60,000 square foot R&D site from Pfizer. The site in Chennai, India will house 250 scientists and is expected to be operational in a few months.